Fig. 2From: Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseasePercent change from baseline in serum HDL and ApoA-I in 32,258 patients from 37 randomized studies. Patients were treated with different doses of statins. a Zocor (simvastatin). b Lipitor (atorvastatin). c Crestor (rosuvastatin). Redrawn with permission from [24]. NS not significantBack to article page